<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568620</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#070770</org_study_id>
    <secondary_id>R01DK070860</secondary_id>
    <secondary_id>GCRC #1710</secondary_id>
    <nct_id>NCT00568620</nct_id>
  </id_info>
  <brief_title>The Role of the Duodenum in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Role of the Duodenum in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In parallel with the increasing prevalence of obesity worldwide, type 2 diabetes mellitus&#xD;
      (T2DM) has reached epidemic proportions. Despite a multitude of available therapies, only&#xD;
      bariatric surgery (e.g., roux-en-Y gastric bypass (GBP)) has proven to be an effective long&#xD;
      term treatment modality for morbid obesity. Moreover, the majority of T2DM patients who&#xD;
      undergo GBP experience normalization of their blood glucose and are able to discontinue their&#xD;
      anti-diabetes medications soon after the procedure. The insulin resistant state commonly seen&#xD;
      in non-diabetic obese subjects also improves after GBP. Evidence from recent animal studies&#xD;
      suggests that the rapid return to euglycemia seen in T2DM patients after GBP might in part&#xD;
      result from excluding the duodenum from the flow of nutrients. With the use of enteral&#xD;
      feeding tubes, we hope to better understand the factors in the human gut that may predispose&#xD;
      obese individuals to the development of insulin resistance and T2DM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incretin effect</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Insulin Resistance and Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1: Nasogastric feeding tube</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Placement of nasojejunal feeding tube</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placement of nasogastric feeding tube</intervention_name>
    <description>Glucose tolerance test via nasogastric feeding tube&#xD;
50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3</description>
    <arm_group_label>1: Nasogastric feeding tube</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nasojejunal feeding tube</intervention_name>
    <description>Glucose tolerance test via nasojejunal feeding tube&#xD;
50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3</description>
    <arm_group_label>2: Placement of nasojejunal feeding tube</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for lean, healthy control subjects:&#xD;
&#xD;
          1. Fasting plasma glucose (FPG) &lt; 100&#xD;
&#xD;
          2. Age 18 to 55&#xD;
&#xD;
          3. BMI 18.5 to 24.9 kg/m2&#xD;
&#xD;
          4. Stable weight for prior 3 months&#xD;
&#xD;
        Inclusion criteria for prediabetic individuals:&#xD;
&#xD;
          1. Based on American Diabetes Association criteria of FPG &gt; 100 and &lt;126&#xD;
&#xD;
          2. Age 18 to 55&#xD;
&#xD;
          3. BMI 35 to 60 kg/m2&#xD;
&#xD;
          4. Stable weight for prior 3 months&#xD;
&#xD;
        Inclusion criteria for diabetic individuals:&#xD;
&#xD;
          1. Diagnosis of type 2 diabetes mellitus (T2DM) for &lt; 5 years&#xD;
&#xD;
          2. Hemoglobin A1c &lt; 8%&#xD;
&#xD;
          3. Age 18 to 55&#xD;
&#xD;
          4. BMI 35 to 60 kg/m2&#xD;
&#xD;
          5. Stable weight for prior 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria for all study subjects:&#xD;
&#xD;
          1. Use of any of the following medications: Thiazolidinediones, dipeptidyl-peptidase IV&#xD;
             (DPP-IV) inhibitors (e.g., sitagliptin), GLP-1 analogs (e.g., exenatide).&#xD;
&#xD;
          2. Subjects with T2DM who are unable to maintain adequate glycemic control (i.e., having&#xD;
             a fasting blood glucose that exceeds 250mg/dL on two consecutive tests) while&#xD;
             temporarily discontinuing their oral diabetes medications for the study and in whom&#xD;
             the study physician determines insulin therapy would not be appropriate.&#xD;
&#xD;
          3. Females with a positive pregnancy test&#xD;
&#xD;
        5. Prior gastric, duodenal, proximal jejunal surgery or pancreas resection 6. Known&#xD;
        malabsorptive disorder 7. History of cancer in past 5 years 8. Renal insufficiency defined&#xD;
        by serum creatinine &gt; 1.5 mg/dl 9. Hepatic enzyme elevations of greater than twice the&#xD;
        upper limits of normal 10. Current use of warfarin or clopidogrel 11. Intercurrent&#xD;
        infections 12. Contraindication to nasogastric or nasojejunal feeding tube (e.g., deviated&#xD;
        nasal septum, prior upper gastrointestinal bleed, or history of easy bleeding) 13.&#xD;
        Residence outside the greater Nashville, TN area&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Naji Abumrad</investigator_full_name>
    <investigator_title>Chairman, Department of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

